Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
about
Clinical Development of a Cytomegalovirus DNA Vaccine: From Product Concept to Pivotal Phase 3 TrialA cytomegalovirus DNA vaccine induces antibodies that block viral entry into fibroblasts and epithelial cells.Comparison of monovalent glycoprotein B with bivalent gB/pp65 (GP83) vaccine for congenital cytomegalovirus infection in a guinea pig model: Inclusion of GP83 reduces gB antibody response but both vaccine approaches provide equivalent protection agaImmunogenicity of varicella zoster virus glycoprotein E DNA vaccineVaccination with Vaxfectin(®) adjuvanted SIV DNA induces long-lasting humoral immune responses able to reduce SIVmac251 Viremia.Developing a Vaccine against Congenital Cytomegalovirus (CMV) Infection: What Have We Learned from Animal Models? Where Should We Go Next?Cytomegalovirus Vaccines: Current Status and Future Prospects.Vaxfectin adjuvant improves antibody responses of juvenile rhesus macaques to a DNA vaccine encoding the measles virus hemagglutinin and fusion proteins.
P2860
Q35826628-51058147-CE53-4652-8032-B9C401B0C691Q36385141-D85447A1-2435-4ABD-BC57-A16F64C0F13DQ36633558-AA916200-AB66-4D64-84A6-8CB442D7D2E2Q36825131-C959B5CD-D7E7-40CF-9D93-AE65076A399FQ37530461-5BFE7A0E-7CBF-4EA3-A9C2-7FE257DF1580Q37574334-10C2DBA5-E754-412D-A64F-59D0FCCB5EC8Q38791353-4498D1DE-C004-4B1B-B8E8-220AB6EFDB05Q42079721-2BEDB39F-4DA9-4626-BCEB-0A8E9D306C27
P2860
Preclinical evaluation of the immunogenicity and safety of plasmid DNA-based prophylactic vaccines for human cytomegalovirus.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Preclinical evaluation of the ...... nes for human cytomegalovirus.
@ast
Preclinical evaluation of the ...... nes for human cytomegalovirus.
@en
type
label
Preclinical evaluation of the ...... nes for human cytomegalovirus.
@ast
Preclinical evaluation of the ...... nes for human cytomegalovirus.
@en
prefLabel
Preclinical evaluation of the ...... nes for human cytomegalovirus.
@ast
Preclinical evaluation of the ...... nes for human cytomegalovirus.
@en
P2093
P2860
P356
P1476
Preclinical evaluation of the ...... ines for human cytomegalovirus
@en
P2093
Alain Rolland
Denis Rusalov
Jane Morrow
John Doukas
Larry R Smith
Mark Shlapobersky
Mary K Wloch
Sean Sullivan
P2860
P304
P356
10.4161/HV.21225
P577
2012-08-24T00:00:00Z